|
Germline DDX41 mutations define a significant entity within adult MDS/AML patients
|
Sep 2019
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS)
|
Jul 2013
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Recent developments in myelodysplastic syndromes
|
Sep 2014
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria
|
Jun 2015
|
Blood
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Reduced ribosomal RNA expression and increased ribosomal DNA promoter methylation in CD34+ cells of patients with myelodysplastic syndromes
|
Oct 2012
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
How we treat lower risk myelodysplastic syndromes.
|
Apr 2013
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
STAT3-mutations indicate the presence of subclinical T cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients.
|
Aug 2013
|
Blood
|
aplastic anemia
|
|
"Moderate" dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution.
|
Sep 2014
|
Blood
|
aplastic anemia
|
|
The myelodysplastic syndrome as a prototypical epigenetic disease.
|
May 2013
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Genetics of Progression From MDS to Secondary Leukemia
|
May 2020
|
Blood
|
myelodysplastic syndromes (MDS)
|
